세계의 사이클로스포린 의약품 시장 보고서(2025년)

Cyclosporine drugs are a class of immunosuppressive medications primarily used to prevent organ rejection following transplants and to treat various autoimmune disorders. These medications work by inhibiting the activity of T-lymphocytes, a type of white blood cell involved in the immune response, thereby reducing inflammation and immune system overactivity.

Cyclosporine drugs come in two main types oral and parenteral. Oral cyclosporine medications are taken by mouth to suppress immune system activity. They are available in several formulations, including capsules, oral solutions, injectables, and topical treatments. These drugs are used for conditions such as organ transplantation, autoimmune disorders, ophthalmic conditions, and dermatological issues, and are prescribed in various settings, including hospitals, specialty clinics, homecare environments, and pharmaceutical retail outlets.

The cyclosporine drugs market research report is one of a series of new reports from The Business Research Company that provides cyclosporine drugs market statistics, including cyclosporine drugs industry global market size, regional shares, competitors with a cyclosporine drugs market share, detailed cyclosporine drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclosporine drugs industry. This cyclosporine drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cyclosporine drugs market size has grown strongly in recent years. It will grow from $1.64 billion in 2024 to $1.75 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historic period can be attributed to several factors, including the rising geriatric population, the increasing use of cyclosporine in ophthalmic treatments, a growing number of clinical trials for cyclosporine-based drugs, increased government support for drug research and development, and a surge in healthcare spending.

The cyclosporine drugs market size is expected to see strong growth in the next few years. It will grow to $2.23 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth projected during the forecast period can be attributed to several factors, including the increasing prevalence of autoimmune diseases, a rise in organ transplant cases, a growing number of patients with dry eye disease, heightened awareness of cyclosporine treatments, and expanding healthcare infrastructure. Key trends expected in the forecast period include advancements in drug delivery systems, improved formulations for cyclosporine drugs, innovation in non-preserved formulations for eye drops, the development of generic cyclosporine drugs, and the adoption of cyclosporine in veterinary medicine.

The growing demand for organ transplantation is expected to drive the expansion of the cyclosporine drugs market. Organ transplantation involves replacing a damaged or failing organ in a person's body with a healthy one from another individual. The rise in organ transplants is largely due to the increasing prevalence of end-stage organ diseases, with advancements in medical diagnostics and treatments extending patient lifespans, allowing more individuals to live long enough to require organ replacements. Cyclosporine drugs play a critical role in organ transplantation by suppressing the immune system's natural response to reject foreign tissues, helping to prevent the transplanted organ from being attacked and damaged by the recipient's immune cells. For example, in December 2024, the Australian Institute of Health and Welfare reported that 938 kidney transplants were performed in Australia in 2022, with 90% being first-time kidney transplants. Among these, 76% came from deceased donors, while 24% were from living donors. As such, the increasing demand for organ transplants is driving the growth of the cyclosporine drugs market.

Leading companies in the cyclosporine drugs market are focusing on developing advanced ophthalmic solutions to deliver targeted treatment directly to the eyes. Ophthalmic medications are specially formulated to treat eye conditions such as infections, inflammation, and dry eye, and are typically available in the form of drops, ointments, or gels. For example, in June 2023, Novaliq GmbH, a Germany-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for VEVYE, the first water-free and preservative-free 0.1% cyclosporine ophthalmic solution. Developed using Novaliq's proprietary EyeSol technology, VEVYE provides an innovative treatment for dry eye disease, demonstrating significant effectiveness within just four weeks. Its unique water-free formulation enhances drug stability, improves patient comfort, and minimizes irritation. This approval represents a major step forward in ophthalmic drug delivery, offering more precise targeting of inflammation in the eyes.

In October 2024, Novaliq GmbH, a Germany-based manufacturer of cyclosporine drugs, entered into a partnership with Laboratoires Thea to launch a ciclosporin eye drop solution in Europe as well as select Middle Eastern and North African (MENA) regions. This collaboration highlights a shared commitment to providing innovative treatments for patients suffering from dry eye disease. The upcoming introduction of Vevizye, a non-preserved cyclosporine eye drop solution, will expand the range of non-preserved treatments available for dry eye relief. Dry eye is a condition that significantly impacts the quality of life for many individuals, and this new treatment aims to offer a highly effective option. Laboratoires Thea is a France-based company that brings its expertise to the partnership, further strengthening the initiative.

Major players in the cyclosporine drugs market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Limited, Astellas Pharma Inc., Apotex Inc., Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals PLC, Santen Pharmaceutical Co. Ltd., Biocon Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Limited, Concord Biotech Limited, CKD Bio Corporation, ChemWerth Inc., Strides Pharma Science Limited, and Fishfa Biogenics.

North America was the largest region in the cyclosporine drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cyclosporine drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cyclosporine drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cyclosporine drugs market consists of sales of therapeutic drug monitoring kits, supportive care medications and cyclosporine active pharmaceutical ingredient. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cyclosporine Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cyclosporine drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cyclosporine drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cyclosporine drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Oral; Parenteral
• 2) By Drug Formulation: Capsules; Oral Solutions; Injectable Forms; Topical Preparations
• 3) By Application: Organ Transplantation; Autoimmune Disorders; Ophthalmic Disorders; Dermatological Disorders
• 4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Pharmaceutical Retail
• Subsegments:
• 1) By Oral: Capsules; Tablets; Oral Solution
• 2) By Parenteral: Intravenous Injection; Intravenous Infusion
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cyclosporine Drugs Market Characteristics

3. Cyclosporine Drugs Market Trends And Strategies

4. Cyclosporine Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cyclosporine Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cyclosporine Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cyclosporine Drugs Market Growth Rate Analysis
• 5.4. Global Cyclosporine Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cyclosporine Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cyclosporine Drugs Total Addressable Market (TAM)

6. Cyclosporine Drugs Market Segmentation

• 6.1. Global Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.2. Global Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsules
• Oral Solutions
• Injectable Forms
• Topical Preparations
• 6.3. Global Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Organ Transplantation
• Autoimmune Disorders
• Ophthalmic Disorders
• Dermatological Disorders
• 6.4. Global Cyclosporine Drugs Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare Settings
• Pharmaceutical Retail
• 6.5. Global Cyclosporine Drugs Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Capsules
• Tablets
• Oral Solution
• 6.6. Global Cyclosporine Drugs Market, Sub-Segmentation Of Parenteral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Injection
• Intravenous Infusion

7. Cyclosporine Drugs Market Regional And Country Analysis

• 7.1. Global Cyclosporine Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cyclosporine Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cyclosporine Drugs Market

• 8.1. Asia-Pacific Cyclosporine Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cyclosporine Drugs Market

• 9.1. China Cyclosporine Drugs Market Overview
• 9.2. China Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cyclosporine Drugs Market

• 10.1. India Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cyclosporine Drugs Market

• 11.1. Japan Cyclosporine Drugs Market Overview
• 11.2. Japan Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cyclosporine Drugs Market

• 12.1. Australia Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cyclosporine Drugs Market

• 13.1. Indonesia Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cyclosporine Drugs Market

• 14.1. South Korea Cyclosporine Drugs Market Overview
• 14.2. South Korea Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cyclosporine Drugs Market

• 15.1. Western Europe Cyclosporine Drugs Market Overview
• 15.2. Western Europe Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cyclosporine Drugs Market

• 16.1. UK Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cyclosporine Drugs Market

• 17.1. Germany Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cyclosporine Drugs Market

• 18.1. France Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cyclosporine Drugs Market

• 19.1. Italy Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cyclosporine Drugs Market

• 20.1. Spain Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cyclosporine Drugs Market

• 21.1. Eastern Europe Cyclosporine Drugs Market Overview
• 21.2. Eastern Europe Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cyclosporine Drugs Market

• 22.1. Russia Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cyclosporine Drugs Market

• 23.1. North America Cyclosporine Drugs Market Overview
• 23.2. North America Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cyclosporine Drugs Market

• 24.1. USA Cyclosporine Drugs Market Overview
• 24.2. USA Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cyclosporine Drugs Market

• 25.1. Canada Cyclosporine Drugs Market Overview
• 25.2. Canada Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cyclosporine Drugs Market

• 26.1. South America Cyclosporine Drugs Market Overview
• 26.2. South America Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cyclosporine Drugs Market

• 27.1. Brazil Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cyclosporine Drugs Market

• 28.1. Middle East Cyclosporine Drugs Market Overview
• 28.2. Middle East Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cyclosporine Drugs Market

• 29.1. Africa Cyclosporine Drugs Market Overview
• 29.2. Africa Cyclosporine Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cyclosporine Drugs Market, Segmentation By Drug Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cyclosporine Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cyclosporine Drugs Market Competitive Landscape And Company Profiles

• 30.1. Cyclosporine Drugs Market Competitive Landscape
• 30.2. Cyclosporine Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Cyclosporine Drugs Market Other Major And Innovative Companies

• 31.1. Intas Pharmaceuticals Limited
• 31.2. Astellas Pharma Inc.
• 31.3. Apotex Inc.
• 31.4. Dr. Reddy's Laboratories Limited
• 31.5. Cipla Limited
• 31.6. Hikma Pharmaceuticals PLC
• 31.7. Santen Pharmaceutical Co. Ltd.
• 31.8. Biocon Limited
• 31.9. Glenmark Pharmaceuticals Limited
• 31.10. Alkem Laboratories Limited
• 31.11. Concord Biotech Limited
• 31.12. CKD Bio Corporation
• 31.13. ChemWerth Inc.
• 31.14. Strides Pharma Science Limited
• 31.15. Fishfa Biogenics

32. Global Cyclosporine Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cyclosporine Drugs Market

34. Recent Developments In The Cyclosporine Drugs Market

35. Cyclosporine Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Cyclosporine Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cyclosporine Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cyclosporine Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer